Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms.
The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors.
The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times on Thursday.
Photo courtesy of AcadeMab Biomedical Inc
The development of COVID-19 antibody drugs focuses on the sequences of the antibodies produced in the body following vaccination, Fong said.
The method does not require any information on the sequences of SARS-CoV-2, she said.
“Specifically, we need to know the DNA sequences of the Y-shaped antibodies carried by people’s memory B cells. Once we obtain the sequences, we can replicate the antibodies,” she added.
The start-up for at least four weeks collected blood samples from five people who had received three doses of COVID-19 vaccines. It then used a method called “cell shorting” to isolate memory B cells and used genetic engineering to decode the sequences of the antibody, AcadeMab Biomedical project manager Chiang Pao-yin (姜伯穎) said.
Getting the right sequences was not easy, Chiang said.
A 20 to 30 milliliter blood sample contains about 40 million cells, from which about 100,000 memory B cells can be isolated, Chiang said.
Using advanced technology, the company initially obtained about 2,000 sequences of antibodies and selected 163 that were expected to be the most effective in fighting against SARS-CoV-2 variants, he said.
“It is like making a key. It must not only have the right shape to fit in the hole, but it also has to be long enough to be used. The right antibodies must not only bind with the spike protein of the virus, but bind firmly,” Chiang said.
The start-up selected 10 sequences and tested them against the Omicron subvariants of SARS-CoV-2 and eventually chose four that showed the most potential, Chiang said, adding that its experimental drug is called SB-001.
Explaining how antibody drugs fight against new SARS-CoV-2 variants while vaccines cannot, Fong said that vaccines and antibody drugs use different mechanisms.
Vaccines prompt the immune system to produce antibodies, but after a given period, only a few antibodies that are most effective against a variant remain in the body, Fong said.
However, it is possible that these antibodies cannot attack new subvariants, she said.
Developers of COVID-19 antibody drugs have deep knowledge of antibody sequences, Fong said.
“It’s like we have a database. We can always research which sequence works best against the latest subvariant and change our formula accordingly,” Fong said.
An antibody that does not work well against an older subvariant could be effective against a new subvariant, she added.
“That has been the case with Eli Lilly and Co. Its first two antibody drugs were approved, but they did not work against later Omicron subvariants. However, the company found another sequence and used it to develop a new antibody drug,” Fong said.
AcadeMab Biomedical is one of only a few Taiwanese companies working on COVID-19 antibody drugs, she said.
Fong said there are two reasons that Taiwanese companies prefer to develop COVID-19 vaccines over antibody drugs, with about 10 firms working on vaccines.
“First, vaccines use fewer proteins than antibody drugs, so vaccine developers can conduct research more easily with limited manufacturing capacity. Second, the requirements for clinical trials involving antibody drugs are much stricter than those for vaccines,” she said.
Antibody drugs are mainly used for treatment instead of prevention, Fong said, adding that they can be used for prevention in some cases, she said.
People who are planning to travel to high-risk areas could take the drugs before embarking on their trip, she said.
As AcadeMab Biomedical focuses on research, it plans to find a manufacturing partner to codevelop SB-001, Fong said, adding that the company has been in talks with several firms and hopes to finalize a deal by the end of this year.
It plans to apply for emergency use authorization in the US and hopes to start phase 1 human trials by June next year, she said.
Taiwan Semiconductor Manufacturing’s (TSMC, 台積電) first wafer fab in Kumamoto, Japan is still set to launch commercial production in the fourth quarter of this year as planned, the world’s largest contract chipmaker said on Saturday in response to reports that mass production might begin ahead of schedule. TSMC said the monthly production capacity of the joint venture fab, Japan Advanced Semiconductor Manufacturing (JASM), is expected to hit 55,000 units of 12-inch wafers, using the mature 12-nanometer, 16-nanometer, 22-nanometer and 28-nanometer processes. JASM is owned by TSMC and its Japanese business partners Sony Semiconductor Solutions Corp and Denso Corp, with the Taiwanese company
US President Joe Biden’s administration is in talks to confer more than US$10 billion in subsidies to Intel Corp, people familiar with the matter said, in what would be the largest award yet under a plan to bring semiconductor manufacturing back to US soil. Intel’s award package is expected to include both loans and direct grants, the source said. They stressed that negotiations are still under way. The US Department of Commerce and Intel declined to comment. The incentives would come from the 2022 Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act, which set aside US$39 billion in direct grants as
A new artificial intelligence (AI) tool that promises to create short videos from simple text commands has raised concerns along with questions from artists and media professionals. OpenAI, the creator of ChatGPT and image generator DALL-E, on Thursday said it was testing a text-to-video model called “Sora” that can allow users to create realistic videos with simple prompts. The San Francisco-based start-up said that Sora can “generate complex scenes with multiple characters, specific types of motion, and accurate details of the subject and background,” but added that it still has limitations, such as possibly “mixing up left and right.” Examples of Sora-created clips
Super Micro Computer Inc’s lengthy rally came to a shuddering halt on Friday, with a selloff that derailed what had looked to be the server maker’s best week on record. Shares fell 20 percent, their biggest one-day percentage drop since August last year. The decline comes in the wake of a nine-session run of gains, the longest such streak for the stock since 2016. However, even with the day’s selloff, the stock rose 8.5 percent for the week. Despite Friday’s drop, recent gains show how Super Micro has become one of the hottest names in artificial intelligence (AI). The stock has risen